lactic acid has been researched along with Delirium of Mixed Origin in 9 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Excerpt | Relevance | Reference |
---|---|---|
"In 8 studies of 235 patients, delirium was associated with: elevated serotonin metabolites, interleukin-8, cortisol, lactate and protein, and reduced somatostatin, β-endorphin and neuron-specific enolase." | 4.87 | A systematic literature review of cerebrospinal fluid biomarkers in delirium. ( Hall, RJ; Maclullich, AM; Shenkin, SD, 2011) |
"The new definitions of sepsis and septic shock reflect the inadequate sensitivity, specify, and lack of prognostication of systemic inflammatory response syndrome criteria." | 2.55 | Sepsis and Septic Shock Strategies. ( Armstrong, BA; Betzold, RD; May, AK, 2017) |
"Postoperative delirium is associated with a breakdown in the BBB." | 1.72 | Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study. ( Blennow, K; Casey, CP; Kunkel, D; Lennertz, RC; Parker, M; Pearce, RA; Rivera, C; Sanders, RD; Tanabe, S; Taylor, J; Zetterberg, H, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (77.78) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
Authors | Studies |
---|---|
Taylor, J | 1 |
Parker, M | 1 |
Casey, CP | 1 |
Tanabe, S | 1 |
Kunkel, D | 1 |
Rivera, C | 1 |
Zetterberg, H | 1 |
Blennow, K | 1 |
Pearce, RA | 1 |
Lennertz, RC | 1 |
Sanders, RD | 1 |
Armstrong, BA | 1 |
Betzold, RD | 1 |
May, AK | 1 |
Kroll, MW | 1 |
Hail, SL | 1 |
Kroll, RM | 1 |
Wetli, CV | 1 |
Criscione, JC | 1 |
Jauchem, JR | 3 |
Rothberger, GD | 1 |
Desai, AK | 1 |
Sharif, S | 1 |
Chawla, SA | 1 |
Shirazian, S | 1 |
Hall, RJ | 1 |
Shenkin, SD | 1 |
Maclullich, AM | 1 |
Abe, K | 1 |
Fujimura, H | 1 |
Nishikawa, Y | 1 |
Yorifuji, S | 1 |
Mezaki, T | 1 |
Hirono, N | 1 |
Nishitani, N | 1 |
Kameyama, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Detection and Neurological Impact of CerebroVascular Events In Noncardiac Surgery PatIents: A COhort EvaluatioN[NCT01980511] | 1,116 participants (Actual) | Observational | 2014-03-24 | Completed | |||
Interventions for Postoperative Delirium: Biomarker-3[NCT03124303] | 310 participants (Anticipated) | Observational | 2017-02-13 | Recruiting | |||
Interventions for Postoperative Delirium: Biomarker-2 (IPOD-B2) Pilot Study[NCT02926417] | 32 participants (Actual) | Observational | 2016-06-30 | Completed | |||
Mortality Due to Septic Shock Associated With Thrombocytopenia in the Intensive Care Unit[NCT03617965] | 350 participants (Anticipated) | Observational | 2018-08-15 | Active, not recruiting | |||
Phase 3 Trial of Coenzyme Q10 in Mitochondrial Disease[NCT00432744] | Phase 3 | 24 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The McMaster Gross Motor Function is a validated scale ranging from 0 to 100 (the higher the better). Since there was the possibility of a subject becoming totally disabled our FDA peer reviewed design called for its use as follows: If the subject completed both periods, the score was calculated as the difference in scores between the end of Period 2 (at 12 months) minus that at the end of Period 1 (6 months). If a subject became totally disabled, this difference was considered as plus infinity if it occurred in period 1 (Penalizes period 1), and minus infinity if it occurred in Period 2 (Penalizes period 2). The two treatments were compared via the Wilcoxon test, and the effect size was estimated using Kendall's Tau-B. This is interpreted in a similar manner to correlation with positive values favoring COQenzyme10 and negative values favoring placebo. One of the links in this report is to the the GMFM scale and how it is scored. A link to the instrument is included. (NCT00432744)
Timeframe: Taken at 6 and 12 Months
Intervention | units on a scale (Median) |
---|---|
Placebo First | -0.002 |
CoenzymeQ10 Frist | -0.12 |
This is a multivariate analysis of the first two outcomes: Period 2 minus Period 1 GMFM88 and Peds Quality of Life, analyzed as follows: First, to be in the analysis, subjects must contribute at least one of these endpoints. Second, if the subject became totally disabled during period 1, the difference was defined as + infinity, (highest possible evidence favoring period 2), and if the subject became totally disabled in period 2, the subject was scored as - infinity (highest possible evidence favoring period 1). Period 2 minus period 1 differences were ranked form low to high with missing values scores at the mid-rank. The Hotelling T-square was computed on these ranks and the P-value was obtained from 100,000 rerandomizations as the fraction of rerandomizations with T-sq at least as large as that observed. (NCT00432744)
Timeframe: end of 12 month minus end of 6 month difference.
Intervention | participants (Number) |
---|---|
Placebo First | 7 |
CoenzymeQ10 Frist | 8 |
"The Pediatric Quality of Life Scale is a validated scale ranging from 0 to 100 (the higher the better). Since there was the possibility of a subject becoming totally disabled our FDA peer reviewed design called for its use as follows: If the subject completed both periods, the score was calculated as the difference in scores between the end of Period 2 (at 12 months) minus that at the end of Period 1 (6 months). If a subject became totally disabled, this difference was considered as plus infinity if it occurred in period 1 (Penalizes period 1), and minus infinity if it occurred in Period 2 (Penalizes period 2). The two treatments were compared via the Wilcoxon test, and the effect size was estimated using Kendall's Tau-B. This is interpreted in a similar manner to correlation with positive values favoring COQenzyme10 and negative values favoring placebo. Goggle pedsQL and Mapi to browse the copyrighted manual. A link to the instrument is included." (NCT00432744)
Timeframe: At 6 and 12 Months
Intervention | units on a scale (Median) |
---|---|
Placebo First | -1.1 |
CoenzymeQ10 Frist | -11.9 |
5 reviews available for lactic acid and Delirium of Mixed Origin
Article | Year |
---|---|
Sepsis and Septic Shock Strategies.
Topics: Anti-Bacterial Agents; Arterial Pressure; Cardiomyopathies; Central Venous Pressure; Critical Care; | 2017 |
Exposures to conducted electrical weapons (including TASER® devices): how many and for how long are acceptable?
Topics: Animals; Blood Glucose; Conducted Energy Weapon Injuries; Creatine Kinase; Delirium; Electric Stimul | 2015 |
Deaths in custody: are some due to electronic control devices (including TASER devices) or excited delirium?
Topics: Acidosis; Animals; Cause of Death; Confounding Factors, Epidemiologic; Delirium; Electroshock; Fever | 2010 |
Pathophysiologic changes due to TASER® devices versus excited delirium: potential relevance to deaths-in-custody?
Topics: Acidosis; Animals; Blood Glucose; Body Temperature; Catecholamines; Channelopathies; Conducted Energ | 2011 |
A systematic literature review of cerebrospinal fluid biomarkers in delirium.
Topics: Acetylcholinesterase; beta-Endorphin; Biomarkers; Brain; Delirium; Dopamine; Humans; Hydrocortisone; | 2011 |
4 other studies available for lactic acid and Delirium of Mixed Origin
Article | Year |
---|---|
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis | 2022 |
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis | 2022 |
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis | 2022 |
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis | 2022 |
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis | 2022 |
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis | 2022 |
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis | 2022 |
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis | 2022 |
Postoperative delirium and changes in the blood-brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study.
Topics: Biomarkers; Blood-Brain Barrier; Delirium; Humans; Interleukin-6; Lactic Acid; Neuroinflammatory Dis | 2022 |
Electrical weapons and excited delirium: shocks, stress, and serum serotonin.
Topics: Adult; Delirium; Electric Stimulation; Female; Healthy Volunteers; Humans; Hydrocortisone; Lactic Ac | 2018 |
The Case | Elevated lactate and osmolar gap after levothyroxine overdose.
Topics: Acidosis; Adult; Calcium Oxalate; Delirium; Drug Overdose; Ethylene Glycol; Female; Humans; Lactic A | 2015 |
Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS).
Topics: Acidosis, Lactic; Adult; Agnosia; Cerebrovascular Disorders; Delirium; Dose-Response Relationship, D | 1991 |